Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients

Liver International

Volumn 31, Issue 8, 2011, Pages 1155-1162

  Huang, Jee Fu ^a,b,c   Dai, Chia Yen ^c,d   Yu, Ming Lung ^c,d,e   Huang, Chung Feng ^b,c   Huang, Ching I ^b,c   Yeh, Ming Lun ^b,c   Yang, Jeng Fu ^c   Hou, Nei Jen ^a   Hsiao, Pi Jung ^c,d   Lin, Zu Yau ^c,d   Chen, Shinn Chern ^c,d   Shin, Shyi Jang ^c,d   Chuang, Wan Long ^c,d  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

Author keywords

Hepatitis C virus; Insulin resistance; Interferon therapy; The homeostasis model assessment model

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79961208346     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02545.x     Document Type: Article

References (36)

1. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when east meets west. J Gastroenterol Hepatol 2009; 24: 336-45.
2. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-9.
3. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
4. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
5. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
6. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol 2007; 102: 1237-43.
7. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997; 4: 9-28.
8. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29: S26-37.
9. Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med 2006; 260: 255-62.
10. Huang JF, Chuang WL, Yu ML, et al. Hepatitis C virus infection and metabolic syndrome - a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci 2009; 25: 299-305.
11. Hsieh MY, Dai CY, Lee LP, et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-7.
12. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
13. Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006; 101: 2752-9.
14. Svegliati-Baroni G, Bugianesi E, Bouserhal T, et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007; 56: 1296-301.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
16. Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006; 49: 99-106.
17. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
18. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.
19. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-8.
20. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
21. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007; 19: 61-6.
22. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1996; 125: 521.
23. Cozzolongo R, Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18: 689-92.
24. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008; 28: 39-46.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: S37-42.
26. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74: 2385-90.
27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
28. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
30. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6.
31. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-65.
32. Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458-62.
33. Fattovich G, Covolo L, Pasino M, et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011; 31: 66-74.
34. Hsieh MH, Lee LP, Hsieh MY, et al. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis 2007; 60: 377-81.
35. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-9.
36. Yang JF, Lin CI, Huang JF, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010; 26: 461-9.